Finance

Lists
AVBP:NASDAQ
Arrivent Biopharma Inc
$13.01
-0.46%
(-0.060) 1D
$12.87
-1.05% (-0.14)
Pre-market
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVBP...
Open
$13.00
High
$13.24
Low
$12.59
Mkt. cap
672.92M
Avg. vol.
2.13M
Volume
2.31K
52-wk high
$35.83
52-wk low
$11.37
EPS
-$3.65
Shares outstanding
51.72M
No. of employees
77
Open
$13.00
High
$13.24
Low
$12.59
Mkt. cap
672.92M
Avg. vol.
2.13M
Volume
2.31K
52-wk high
$35.83
52-wk low
$11.37
EPS
-$3.65
Shares outstanding
51.72M
No. of employees
77
News stories
From web sources and news partners
About Arrivent Biopharma Inc
CEO-
Employees77
Founded2021
HeadquartersNewtown Square, Pennsylvania, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 11 analysts giving stock ratings to AVBP in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for AVBP in the last 3 months.
Highest
Current $13.01
$30.00 (+130.59%)
Average
$24.20 (+86.01%)
Lowest
$15.00 (+15.30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yigal Nochomovitz
Citi
Buy
Maintained
$23.00
+76.8%
11/11/2026
Supawat Thongthip
Truist Financial
Buy
Maintained
$24.00
+84.5%
11/10/2026
Boris Peaker
JonesTrading
Buy
Maintained
$22.00
+69.1%
11/10/2026
Jeff Jones
Oppenheimer
Buy
Maintained
$25.00
+92.2%
11/10/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$27.00
+107.5%
11/10/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$29.00
+122.9%
11/09/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$30.00
+130.6%
10/26/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
-
-
10/25/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$29.00
+122.9%
10/20/2026
Kelly Shi
Jefferies
Buy
Maintained
$18.00
+38.4%
10/06/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$15.00
+15.3%
10/06/2026
Asthika Goonewardene
Leerink Partners
Buy
Maintained
$45.00
+245.9%
08/13/2026
Soumit Roy
JonesTrading
Buy
Maintained
$45.00
+245.9%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
5.00M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
32.18M
37.62M
42.34M
38.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.65M
8.49M
10.35M
9.48M
Operating expense
38.82M
46.11M
52.69M
48.38M
Total operating expenses
38.82M
46.11M
52.69M
48.38M
Operating income
-38.82M
-46.11M
-52.69M
-43.38M
Other non operating income
-
-
-
-
EBT including unusual items
-35.96M
-43.32M
-49.89M
-40.51M
EBT excluding unusual items
-35.54M
-43.32M
-49.89M
-40.31M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-35.96M
-43.32M
-49.89M
-40.51M
Net profit margin
-
-
-
-810.24%
Earnings per share
-0.78
-0.96
-1.05
-0.81
Interest and investment income
3.28M
2.79M
2.80M
3.06M
Interest expense
-
-
-
-
Net interest expenses
3.28M
2.79M
2.80M
3.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps